Semaglutide has recently been shown to induce clinically significant weight loss in patients with obesity that is sustained for as long as the drug is given. Tom Wadden, PhD, from the University of Pennsylvania, discusses results from the series of recent STEP trials and how they compare to the effects of other medications used to treat obesity.
Authors have declared conflicts of interest related to the article discussed in this podcast. Visit the article on jama.com for the complete disclosure.
Subscribe on your favorite podcast source to receive future episodes of this podcast. Learn more about this JAMA Network podcast here
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
or
You currently have no searches saved.
You currently have no courses saved.